Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

NCT06975293 is registered in ClinicalTrials.gov with STORM Therapeutics LTD as lead sponsor.

NCT NCT06975293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Lead sponsor
STORM Therapeutics LTD
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 5, 2025
Completion date
June 29, 2028
Enrollment
107 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

dedifferentiated liposarcoma, leiomyosarcoma, sarcoma, solid tumor